VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $465.000 thousand which beat the analyst consensus estimate of $320.000 thousand by 45.31 percent. This is a 3.20K percent increase over sales of $(15.000 thousand) the same period last year.